A Chinese biotech firm has landed one of the largest licensing deals ever struck for an mRNA-based therapy, underscoring how aggressively global pharmaceutical giants are moving to secure access to China’s expanding pipeline of experimental drugs.

Suzhou-based Abogen Biosciences said Friday that Novartis has agreed to pay $575 million upfront for exclusive worldwide rights to ABO2203, an experimental treatment designed to deplete B cells that drive autoimmune conditions such as lupus and rheumatoid arthritis. The Swiss drugmaker could pay up to $7.2 billion more in milestone payments tied to development, regulatory and commercial progress, bringing the total potential value of the agreement to about $7.8 billion.

Abogen could also receive royalties on future product sales, the companies said.

The transaction remains subject to customary closing conditions, including regulatory approvals.

ABO2203 represents a novel application of messenger RNA technology beyond the vaccine space where it first gained prominence. The drug candidate is an mRNA-encoded CD19xCD3 T-cell engager: lipid nanoparticles deliver mRNA that instructs a patient’s own cells to produce the engager inside the body, rather than in a manufacturing plant. The molecule works as a bridge, binding CD3 on T cells with one arm and CD19 on B cells with the other, drawing killer T cells directly onto the immune cells that drive disease. Those B cells are central drivers of lupus, rheumatoid arthritis and other autoimmune conditions.

The mechanism is intended to offer a fundamentally different approach to B-cell depletion compared with existing therapies, potentially resetting the immune system rather than merely suppressing symptoms.

Human data is beginning to accumulate. In a study published in the journal Cell in September, three patients with treatment-refractory immune thrombocytopenia, a condition in which the immune system destroys platelets, achieved sustained complete remission through six months. ABO2203 cleared CD19-positive B cells from both peripheral blood and bone marrow, and none of the patients developed cytokine release syndrome, a severe inflammatory reaction that has complicated other T-cell-engaging therapies. The researchers said the drug can be given as an outpatient subcutaneous injection without lymphodepletion or premedication, and that its half-life of seven to 11 days contrasts with about two hours for Amgen’s Blincyto, the first approved CD19xCD3 T-cell engager, which must be given by continuous infusion. An early-stage trial in B-cell non-Hodgkin lymphoma has provided additional safety and pharmacokinetic evidence. “ABO2203 is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases,” Abogen Chief Executive Officer Bo Ying said in a statement.

Beyond ABO2203, the agreement gives Novartis options to license additional experimental medicines developed on Abogen’s RNA technology platform. This structure allows the pharmaceutical major to hedge its bet on a broader pipeline while anchoring its initial commitment to a single lead asset.

The deal structure follows the industry-standard template of upfront payment plus milestone payments plus royalties:

ComponentValueUpfront payment$575 millionPotential milestone paymentsUp to $7.2 billionTotal potential deal valueAbout $7.8 billionRoyalties on future salesYes (terms undisclosed)

Note: Figures reflect the maximum potential payout if all development, regulatory and commercial milestones are achieved and Novartis exercises its options on additional Abogen programs.

The transaction marks a strategic pivot for Novartis in the autoimmune space. The company paused development of its autologous CD19 CAR-T therapy rapcabtagene autoleucel, or rap-cel, in autoimmune diseases in late August after three patient deaths caused by immune effector cell-associated hemophagocytic syndrome, a severe inflammatory complication. Bristol Myers Squibb simultaneously paused enrollment in its own autoimmune CAR-T program. Novartis has said its oncology trials of rap-cel are not affected. The move toward an mRNA-based mechanism suggests the company is recalibrating its autoimmune pipeline strategy.

For Abogen, a clinical-stage biotechnology company with programs spanning oncology, autoimmune diseases and vaccines, the deal validates the commercial potential of its RNA platform. The company’s lead vaccine candidate, ABO1108, an mRNA-based shingles vaccine, is currently in Phase 3 trials in China.

The agreement is the latest in a rapid succession of deals in which multinational pharmaceutical companies have placed substantial bets on Chinese biotech innovation.

This week alone, Novo Nordisk agreed to pay $300 million upfront, and as much as $2.6 billion in total, for rights outside mainland China to HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist from Jiangsu Hengrui Pharmaceuticals that is still in preclinical testing. AstraZeneca agreed to invest $2 billion in Summit Therapeutics through newly issued equity, accelerating development of ivonescimab, a PD-1/VEGF bispecific antibody originating from Akeso, in combination with antibody-drug conjugates. GSK earlier agreed to acquire a trispecific T-cell engager for multiple myeloma from Chimagen Biosciences for up to $750 million, its second deal with the Chinese company.

The four deals at a glance:

AcquirerPartnerAssetFocusValueNovo NordiskHengrui PharmaceuticalsHRS-1596Once-weekly oral GLP-1/GIP agonist, preclinicalUp to $2.6 billionAstraZenecaSummit TherapeuticsIvonescimab (from Akeso) plus ADCsPD-1/VEGF bispecific combinations$2 billion equity investmentGSKChimagen BiosciencesTrispecific T-cell engagerMultiple myeloma, clinic entry planned for 2027Up to $750 millionNovartisAbogen BiosciencesABO2203mRNA-encoded CD19xCD3 T-cell engager, Phase 1Up to $7.8 billion

The flurry of transactions reflects a structural shift in how large pharmaceutical companies are replenishing their pipelines. Facing pressure on their internal R&D productivity, global drugmakers are increasingly turning to Chinese biotech firms, which offer differentiated technology platforms and competitive licensing terms.

For Novartis, the deal adds an experimental autoimmune treatment to its pipeline while extending its reach into RNA technology beyond vaccines. For Abogen, it provides substantial non-dilutive capital to advance its broader portfolio while retaining upside through milestone payments and royalties.

The potential patient base extends well beyond China. Japan has an estimated 60,000 to 100,000 people with systemic lupus erythematosus, according to the Japanese Society of Internal Medicine, and about 825,000 with rheumatoid arthritis, according to the Japan College of Rheumatology.

The agreement also signals growing international confidence in the quality of Chinese biotech innovation, particularly in platform technologies like mRNA that have broad therapeutic applicability. As more such deals close, China’s position in the global drug development ecosystem continues to strengthen.